Mycobacterium Tuberculosis Infection Clinical Trial
Official title:
A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and immunogenicity of VPM1002 against Mtb infection.
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and immunogenicity of VPM1002 against Mtb infection. Healthy male or female newborn infants will be centrally randomized to receive the allocated vaccine, stratified by the HIV status of the mother. Single dose of VPM1002 or BCG SII will be administered (within 14 days of birth) strictly intradermally. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04493671 -
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT05285202 -
Clinic-based Versus Hotspot-focused Active TB Case Finding
|
N/A | |
| Completed |
NCT05526911 -
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
|
Phase 1 |